Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:umu-128137" > Patient Heterogenei...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Hoogendoorn, MartineErasmus University Rotterdam (author)

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease : Are Current Models Suitable to Evaluate Personalized Medicine?

Article/chapterEnglish2016

Publisher, publication year, extent ...

Elsevier BV,2016
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:umu-128137
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-128137URI
https://doi.org/10.1016/j.jval.2016.04.002DOI
https://lup.lub.lu.se/record/d3980d87-6687-4483-b684-c0753eb85e46URI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

OBJECTIVES: To assess how suitable current chronic obstructive pulmonary disease (COPD) cost-effectiveness models are to evaluate personalized treatment options for COPD by exploring the type of heterogeneity included in current models and by validating outcomes for subgroups of patients.METHODS: A consortium of COPD modeling groups completed three tasks. First, they reported all patient characteristics included in the model and provided the level of detail in which the input parameters were specified. Second, groups simulated disease progression, mortality, quality-adjusted life-years (QALYs), and costs for hypothetical subgroups of patients that differed in terms of sex, age, smoking status, and lung function (forced expiratory volume in 1 second [FEV1] % predicted). Finally, model outcomes for exacerbations and mortality for subgroups of patients were validated against published subgroup results of two large COPD trials.RESULTS: Nine COPD modeling groups participated. Most models included sex (seven), age (nine), smoking status (six), and FEV1% predicted (nine), mainly to specify disease progression and mortality. Trial results showed higher exacerbation rates for women (found in one model), higher mortality rates for men (two models), lower mortality for younger patients (four models), and higher exacerbation and mortality rates in patients with severe COPD (four models).CONCLUSIONS: Most currently available COPD cost-effectiveness models are able to evaluate the cost-effectiveness of personalized treatment on the basis of sex, age, smoking, and FEV1% predicted. Treatment in COPD is, however, more likely to be personalized on the basis of clinical parameters. Two models include several clinical patient characteristics and are therefore most suitable to evaluate personalized treatment, although some important clinical parameters are still missing.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Hälsovetenskap Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi hsv//swe
MEDICAL AND HEALTH SCIENCES Health Sciences Health Care Service and Management, Health Policy and Services and Health Economy hsv//eng
COPD
model
patient heterogeneity
validation
COPD
model
patient heterogeneity
validation

Added entries (persons, corporate bodies, meetings, titles ...)

Feenstra, Talitha LUniversity of Groningen,National Institute for Public Health and the Environment (RIVM) (author)
Asukai, YumiIMS Health Sweden AB (author)
Briggs, Andrew HUniversity of Glasgow (author)
Borg, SixtenLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics,Evidera Ltd(Swepub:lu)med-sxb (author)
Dal Negro, Roberto WNational Center for Respiratory Pharmacoeconomics and Pharmacoepidemiology (author)
Hansen, Ryan NUniversity of Washington (author)
Jansson, Sven-ArneUmeå University,Umeå universitet,Yrkes- och miljömedicin,The OLIN Unit(Swepub:umu)svja0005 (author)
Leidl, ReinerHelmholtz Zentrum München (author)
Risebrough, NancyICON Health Economics (author)
Samyshkin, YevgeniyIMS Health Sweden AB (author)
Wacker, Margarethe EHelmholtz Zentrum München (author)
Rutten-van Mölken, Maureen P M H (author)
Erasmus University RotterdamUniversity of Groningen (creator_code:org_t)

Related titles

In:Value in Health: Elsevier BV19:6, s. 800-8101098-30151524-4733

Internet link

Find in a library

Value in Health (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Hoogendoorn, Mar ...; Feenstra, Talith ...; Asukai, Yumi; Briggs, Andrew H; Borg, Sixten; Dal Negro, Rober ...; show more...; Hansen, Ryan N; Jansson, Sven-Ar ...; Leidl, Reiner; Risebrough, Nanc ...; Samyshkin, Yevge ...; Wacker, Margaret ...; Rutten-van Mölke ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Health Sciences; and Health Care Serv ...

Articles in the publication: Value in Health

By the university: Umeå University; Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se